- The study compared the effectiveness of post-transplant cyclophosphamide (PTCy) with methotrexate (MTX) and cyclosporine-A (CsA) in preventing graft-versus-host disease (GVHD) in patients receiving peripheral blood stem cell transplants from matched related donors.
- Among the 75 patients in each group, those receiving PTCy/CSA experienced significantly lower rates of chronic GVHD (13.4%) compared to those on MTX/CsA (38.6%).
- Overall survival and disease-free survival rates were similar for both groups after two years, indicating that while PTCy may offer benefits in reducing chronic GVHD, it does not significantly improve survival